Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) amended pricing for a non‑brokered private placement dated February 12, 2026. The company intends to issue up to 3,076,923 Units at $0.65 per Unit for gross proceeds up to $2,000,000.
Each Unit includes one common share and one warrant exercisable at $0.75 for three years. The company will issue Admin Fee Shares equal to 1.0% of placement Shares, may pay finders' fees or issue finders' warrants, and will use proceeds for general corporate, R&D and investor relations. Closing is subject to regulatory approvals; securities carry a four‑month plus one‑day hold.
Onco-Innovations (OTCQB:ONNVF) filed a preliminary base shelf prospectus dated February 3, 2026 with Canadian provincial securities regulators. The filing is preliminary and not final; securities may not be sold until a final receipt and prospectus supplement are obtained.
The shelf, if finalized, would permit the company to offer common shares, debt securities, warrants, subscription receipts and units over a 25-month effective period to provide financial flexibility. Securities are not registered for sale in the United States and may not be offered there absent registration or an exemption. A copy is available on SEDAR+ under the company profile.
Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 2,272,727 Units at $0.88 per Unit to raise gross proceeds of up to $2,000,000. Each Unit includes one common share and one-half warrant, with each whole warrant exercisable to buy one share at $1.10 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of Shares issued in the placement to an arm's-length third party and may pay finders' fees or issue finders' warrants on warrant terms. Closing is subject to regulatory approvals; securities will carry a four-month-plus-one-day hold. Proceeds are intended for general corporate, working capital, R&D and investor relations purposes. Securities are not registered for sale in the United States.
Onco-Innovations (OTCQB:ONNVF) engaged i2i Marketing Group LLC to provide market awareness and corporate communications services, including content creation, project management, third-party media distribution, and digital market awareness initiatives.
The initial budget for the i2i program is USD $400,000, scheduled to run until July 14, 2026 or until the budget is exhausted, with ongoing evaluation and optimization. The company also obtained a return of the remaining unused balance of €213,000 from a prior market awareness provider. The company disclosed that i2i holds no direct or indirect interest in its securities.
Onco-Innovations (OTCQB:ONNVF) chaired Colorectal Cancer Canada’s fourth Catalysts roundtable, Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held virtually on December 2, 2025. The invitation-only session gathered ~20 senior leaders from industry, government, academic medicine, and clinical programs to discuss national scalability, data governance, interoperability, and transportable evidence for precision oncology.
Speakers included leaders from BC Cancer, University of Calgary, Inka Health, and others. Next steps: an internal roundtable report, a 2026 manuscript integrating series insights, advocacy materials on data innovation, and formation of working groups to advance AI-enabled precision medicine.
Onco-Innovations (OTCQB:ONNVF) announced on December 7, 2025 that it has engaged a U.S. investment bank to advise on a potential Nasdaq cross-listing and to evaluate a possible concurrent equity financing.
The advisory mandate covers analysis of listing requirements, regulatory and governance considerations, and capitalization strategies to support a U.S. cross-listing. The company said the structure and terms of any financing are not finalized and that there is no assurance a cross-listing or financing will be completed.
Onco-Innovations (OTCQB:ONNVF) attended the University of Alberta's 2025 Innovation Awards on November 21, 2025, highlighting its 2024 exclusive license of the PNKP Inhibitor Technology from the university.
The technology, developed over more than 15 years, is supported by nine issued patents and aims to sensitize cancer cells to chemotherapy and radiation by delaying DNA repair. Onco-Innovations said it is advancing preclinical development and IND-enabling studies toward clinical evaluation. The company also approved issuance of 60,000 Restricted Share Units to certain directors under its equity incentive plan.
Onco-Innovations (OTCQB:ONNVF) said Dalton Pharma Services began optimization and intermediate scale-up for its proprietary PNKP inhibitor A83B4C63 on November 20, 2025. The program advances from prior preclinical manufacturing to pilot-scale, non‑GMP synthesis using Dalton's FDA- and Health Canada‑approved Toronto facility.
Key activities include intermediary batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4, analytical method qualification, ICH‑guided stability testing, and a formal safety and risk assessment to support future GMP production and IND‑enabling work toward Phase 1 studies.
Onco-Innovations (OTCQB:ONNVF) announced a pilot collaboration with Kuano to accelerate development of its PNKP Inhibitor Technology (A83B4C63) using AI, molecular modelling and Kuano's quantum-ready analytics.
The pilot runs through Q4 2025 and aims to deliver validated platform outputs, structural binding models, and mechanistic hypotheses to guide structure optimization, generative design, toxicity mapping, and preclinical candidate selection.
Onco-Innovations (OTCQB:ONNVF) announced that subsidiary Inka Health published a technical primer titled Transportability of Non-Local Real-World Evidence in the Journal of Clinical Evaluative Research on November 7, 2025. The primer outlines three foundational principles — consistency, positivity, conditional exchangeability — and describes statistical techniques (matching, weighting, standardization, bias analysis) to adapt non-local RWE for Health Technology Assessment.
Inka Health plans to integrate these methods into its SynoGraph platform to support cross-border oncology evidence use, especially for rare diseases with limited local data.